As on Wednesday, Ocular Therapeutix Inc (NASDAQ: OCUL) started slowly as it slid -0.26% to $11.42, before settling in for the price of $11.45 at the close. Taking a more long-term approach, OCUL posted a 52-week range of $5.78-$16.44.
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 8.51%. Meanwhile, its Annual Earning per share during the time was 8.51%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -19.10%. This publicly-traded company’s shares outstanding now amounts to $213.05 million, simultaneously with a float of $186.31 million. The organization now has a market capitalization sitting at $2.43 billion.
Ocular Therapeutix Inc (OCUL) Ownership Facts and Figures
Another important factor to analyze is how key investors are playing towards the stock of the Biotechnology industry. Ocular Therapeutix Inc’s current insider ownership accounts for 12.55%, in contrast to 79.26% institutional ownership. According to the most recent insider trade that took place on Nov 24 ’25, this organization’s Chief Strategy Officer sold 1,878 shares at the rate of 12.04, making the entire transaction reach 22,611 in total value, affecting insider ownership by 277,860. Preceding that transaction, on Nov 24 ’25, Company’s insider sold 19,530 for 12.04, making the whole transaction’s value amount to 235,141. This particular insider is now the holder of 3,157,960 in total.
Ocular Therapeutix Inc (OCUL) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.34 per share during the current fiscal year.
Ocular Therapeutix Inc’s EPS decrease for this current 12-month fiscal period is -19.10% and is forecasted to reach -1.41 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 3.52% through the next 5 years, which can be compared against the 8.51% growth it accomplished over the previous five years trading on the market.
Ocular Therapeutix Inc (NASDAQ: OCUL) Trading Performance Indicators
Let’s observe the current performance indicators for Ocular Therapeutix Inc (OCUL). It’s Quick Ratio in the last reported quarter now stands at 7.78. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 43.62.
In the same vein, OCUL’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.44, a figure that is expected to reach -0.32 in the next quarter, and analysts are predicting that it will be -1.41 at the market close of one year from today.
